Smith Thomas B 4
4 · COLLEGIUM PHARMACEUTICAL, INC · Filed Feb 12, 2026
Research Summary
AI-generated summary of this filing
Collegium (COLL) EVP Thomas B. Smith Receives Awards
What Happened
- Thomas B. Smith, EVP and Chief Medical Officer of Collegium Pharmaceutical (COLL), was granted awards and recognized vesting of performance shares on Feb 10, 2026. He received a total of 37,042 equity awards (14,268 RSUs and 22,774 PSUs). To satisfy tax withholding obligations upon vesting, 17,435 shares were withheld/disposed at $46.75 per share, generating proceeds of $815,087 (5,897 shares = $275,685; 11,538 shares = $539,402). These transactions reflect awards/vesting and tax-withholding, not open-market selling.
Key Details
- Transaction date: February 10, 2026; Form 4 filed February 12, 2026 (no late filing flagged in the report).
- Awarded: 14,268 RSUs (see vesting schedule below) and 22,774 PSUs (performance-vesting determined met).
- Shares withheld/disposed to cover taxes: 17,435 shares at $46.75 each, total ~$815,087.
- Shares owned after transaction: not specified in the filing.
- Relevant footnotes:
- RSUs (F1): Each RSU converts to one share; 33% vest Feb 10, 2027, remainder vests in equal annual installments over the next two years, subject to continued service; settled in shares on vesting.
- PSUs (F3): 22,774 PSUs from prior grants were deemed to have met performance criteria and were converted to shares.
- Withholding (F4, F5): 11,538 and 5,897 shares were withheld to satisfy taxes on the PSUs and RSUs, respectively.
- F2 notes small additional purchases via the employee stock purchase plan in 2025–2026 that are included in holdings history.
Context
- These transactions are award/vesting-related: the PSUs vested based on achieved performance goals and RSUs were granted with a multi-year vesting schedule. The "disposed" shares are a tax-withholding mechanism (issuer withheld shares to cover payroll/tax obligations), not an open-market sale — often routine when equity awards vest.
Insider Transaction Report
Form 4
Smith Thomas B
EVP and Chief Medical Officer
Transactions
- Award
Common Stock
[F1][F2]2026-02-10+14,268→ 85,312 total - Award
Common Stock
[F3]2026-02-10+22,774→ 108,086 total - Tax Payment
Common Stock
[F4]2026-02-10$46.75/sh−5,897$275,685→ 102,189 total - Tax Payment
Common Stock
[F5]2026-02-10$46.75/sh−11,538$539,402→ 90,651 total
Footnotes (5)
- [F1]Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. One-third (33%) of the RSUs shall vest on February 10, 2027, with the balance of the RSUs vesting in equal annual installments over the following two-year period, subject to the Reporting Person's continued service with the Issuer. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
- [F2]Includes 376 and 404 shares acquired on July 18, 2025 and January 16, 2026, respectively, under the Issuer's employee stock purchase plan.
- [F3]Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 22,774 performance share units ("PSUs") granted in the Issuer's three prior fiscal years.
- [F4]Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of PSUs.
- [F5]Shares withheld by the Issuer to satisfy applicable withholding taxes upon the vesting of RSUs.
Signature
/s/ Colleen Tupper as Attorney-In-Fact For Thomas B. Smith, MD|2026-02-12